Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 112 posts found.

shutterstock_311949818

Neurodegenerative market to be worth $45 billion by 2022

December 12, 2016
Sales and Marketing Biogen, GBI Research, Novartis, Roche, Sanofi, neurodegenerative

Neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) form a lucrative worldwide market which …

News
biogen_austria_238

Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint

November 7, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …

News
biogen_austria_238

Biogen closes in on bringing muscular atrophy preventing drug to market

September 26, 2016
Manufacturing and Production, Research and Development Biogen, EMA, FDA, Nusinersen

Biogen has applied for Priority Review, which, if granted, would shorten the review period necessary for nusinersen. They also plan …

News

FDA fast track designation for Biogen’s investigational Alzheimer’s treatment

September 2, 2016
Medical Communications, Research and Development Alzheimer's, Alzheimer’s, Biogen, FDA, aducanumab, fast track

Biogen has announced that its investigational Alzheimer’s disease treatment aducanumab has been granted fast track designation by the FDA. The …

News
biogen_austria_238

Biogen names haemophilia spin-off Bioverativ

August 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, bioverativ

Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …

News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …

News
biogen_austria_238

Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III

August 2, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …

News
biogen_austria_238

George Scangos to step down as Biogen CEO

July 21, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, George Scangos

In a surprising move, Biogen used the publishing of some promising second quarter results to announce the departure of CEO …

News
logo_400x400

Biogen and AbbVie’s Zinbryta gets European backing to treat multiple sclerosis

July 7, 2016
Research and Development, Sales and Marketing Biogen, drug approval, european union, multiple sclerosis, zinbryta

Biogen (Nasdaq: BIIB) and Abbvie’s (NYSE: ABBV) once-monthly Zinbryta (daclizumab) has been approved in European Union for treatment of multiple …

News
stocks1

Weekly Movers: Lion Biotech, Adamis, Sarepta…

June 13, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta

Drug trial results remained the important theme over the past week with several companies announcing key study results. The trial …

Feature
samsung

New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016

June 8, 2016
Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5

Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …

News
biogen_austria_238

Biogen MS drug misses primary endpoint in Phase II trial

June 8, 2016
Research and Development Biogen, MS, multiple sclerosis, opicinumab

Biogen has reported top-line results in the Phase II trial evaluating opicinumab (anti-Lingo-1) in relapsing forms of multiple sclerosis, with …

News
biogen_austria_238

Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme

June 2, 2016
Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval

Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …

News
biogen_idec_hillerod_2008

Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …

News
samsung_bioepis

EU green-lights Samsung Bioepis, Biogen’s Remicade biosimilar Flixabi

May 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Samsung Bioepis, biosimilar, drug trial, regulation, research

Samsung Bioepis and partner Biogen (Nasdaq: BIIB) said the European Commission has approved Flixabi, a biosimilar version of Johnson & …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024